Other Biotech IPOs stayed at slow pace, but grew larger in the first quarter of 2026 pharminent March 31, 2026
Other Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team Photo pharminent March 31, 2026
Regulatory S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD pharminent March 30, 2026
Clinical Data Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout pharminent March 30, 2026
Regulatory Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug pharminent March 30, 2026
Clinical Data Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline pharminent March 30, 2026
Market Access The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments pharminent March 30, 2026
Other S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC pharminent March 27, 2026
Regulatory Accord, Intas, and Bio-Thera File Four IPRs Against Janssen Golimumab Patents pharminent March 27, 2026
M&A / Deals Novartis targets Xolair successor in buyout of startup Excellergy pharminent March 27, 2026
M&A / Deals Merck’s deal for Terns sparks debate over a possible biotech bidding war pharminent March 26, 2026
Regulatory FDA clears Denali drug in ‘clear step’ for rare disease biotechs pharminent March 26, 2026
Clinical Data Wave crashes on obesity drug update; Kodiak’s reboot pays dividends pharminent March 26, 2026
M&A / Deals Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug pharminent March 25, 2026
M&A / Deals Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases pharminent March 24, 2026
Clinical Data Karyopharm myeloma drug yields mixed data in myelofibrosis trial pharminent March 24, 2026
M&A / Deals Immutrin raises $87M to advance drug for progressive heart disease pharminent March 24, 2026
Regulatory FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares pharminent March 24, 2026
Other NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers pharminent March 24, 2026
Business Pipeline How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup pharminent March 24, 2026
Regulatory Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results pharminent March 23, 2026
